2022 Annual Business Report


Our integrated business model has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.


The strength of an integrated business model

Our deep understanding of vaccine science, our proven R&D capabilities and manufacturing infrastructure have been established to develop and commercialize our two successful travel vaccines. We are currently focusing our R&D capabilities on our vaccine candidates against Lyme disease, chikungunya and COVID-19.

Deep understanding of vaccine science

Valneva’s development programs benefit from its deep understanding of vaccine science including its expertise across multiple vaccine modalities.

R&D capabilities

Valneva’s R&D capabilities comprise all key functions needed to support the development of vaccines to licensure. Our R&D operations encompass more than 200 employees, most of whom are located in Vienna (Austria).

Manufacturing expertise and infrastructure

Valneva’s manufacturing network has been operating and producing licensed vaccines for more than 10 years and the Company believes it has the expertise and capability to produce most types of viral or bacterial vaccines.

Marketing & Distribution network

Valneva has developed a commercial presence in many key travel vaccine markets (Read more). The Company has also continued to leverage its commercial organization to distribute third-party products and aim to attract additional products to further leverage its commercial infrastructure.